Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FADS1 | O60427 | 4/20 | 0.55 |
| ▸ | GSK3A | P49840 | 2/20 | 0.49 |
| ▸ | GSK3B | P49841 | 2/20 | 0.49 |
| ▸ | RIPK2 | O43353 | 3/20 | 0.47 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.45 |
| ▸ | GAK | O14976 | 1/20 | 0.45 |
| ▸ | LCK | P06239 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.45 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.45 |
| ▸ | GRM4 | Q14833 | 6/20 | 0.42 |
| ▸ | ITK | Q08881 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12325161 | 0.86 | TRPA1 (0.46) | FADS1TGFBR1GRM4 | |
| SCHEMBL12325165 | 0.82 | TGFBR1 (0.40) | FADS1GSK3AGSK3BTGFBR1GRM4 | |
| SCHEMBL12325176 | 0.81 | TRPA1 (0.55) | FADS1TGFBR1GRM4 | |
| SCHEMBL14634187 | 0.78 | GSK3A (0.48) | FADS1GSK3AGSK3BRIPK2TGFBR1 | |
| SCHEMBL12325164 | 0.77 | FADS1 (0.43) | FADS1GRM4ITK | |
| SCHEMBL14633578 | 0.76 | GSK3A (0.44) | FADS1GSK3AGSK3BRIPK2TGFBR1 | |
| SCHEMBL14634300 | 0.75 | TGFBR1 (0.36) | GSK3AGSK3BTGFBR1GRM4ITK | |
| SCHEMBL2435894 | 0.75 | KDR (0.46) | FADS1RIPK2TGFBR1GAKLCK | |
| SCHEMBL12325172 | 0.74 | TGFBR1 (0.38) | FADS1TGFBR1GRM4EGFR | |
| SCHEMBL12325163 | 0.74 | TGFBR1 (0.42) | FADS1TGFBR1GRM4EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2552211-A1 | INDAZOLYL-PYRIMIDINES AS KINASE INHIBITORS | Glaxo Group Limited (GB) | 2013-02-06 | — | — | EP | disclosed |
| US-20130023532-A1 | INDAZOLYL-PYRIMIDINES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2013-01-24 | — | — | US | disclosed |
| US-20130023532-A1 | INDAZOLYL-PYRIMIDINES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2013-01-24 | — | — | US | disclosed |
| US-20130023532-A1 | INDAZOLYL-PYRIMIDINES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2013-01-24 | — | — | US | disclosed |
| WO-2011120025-A1 | INDAZOLYL-PYRIMIDINES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2011-09-29 | — | — | WO | disclosed |
| WO-2011120025-A1 | INDAZOLYL-PYRIMIDINES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2011-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130023532-A1 | INDAZOLYL-PYRIMIDINES AS KINASE INHIBITORS | MAP3K19, MAP3K1, MAP3K20 | FADS1 3869/4885GSK3A 644/4885GSK3B 896/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.